Study title:
QT interval prolongation and risk of life-threatening arritmias during toxoplasmosis with spiramycin in neonates - Marco Stramba-Badiale, MD, PhD, Filippi Nador, MD, Norberto Porta, MD, Stephano Guffanti, MD (Stramba-Badiale et al) in American Heart Jounal, 1997, vol 133, number 1
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Parasitic Diseases [C03]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: SPIRAMYCIN |
ATC code: J01FA02 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|